BN Business News
Add your company to Business Communicator →

Technology · 14/10/2026Updated: 10/17/2026 · 1 min read

EMA Approves Paediatric Investigation Plan for Opdualag and Two Other Cancer Treatments

The European Medicines Agency (EMA) has agreed to investigate Opdualag, nivolumab, and relatlimab for use in children with certain types of cancer, including benign, malignant, and unspecified neoplasms.

Original source language: EMA — Paediatric Investigation PlansOpen original release →

Explore insights

Business insights →